Literature DB >> 29136619

Risk Factor Analysis for AKI Including Laboratory Indicators: a Nationwide Multicenter Study of Hospitalized Patients.

Sasa Nie1, Zhe Feng1, Li Tang1, Xiaolong Wang1, Yani He2, Jingai Fang3, Suhua Li4, Yibin Yang5, Huijuan Mao6, Jundong Jiao7, Wenhu Liu8, Ning Cao9, Wenge Wang10, Jifeng Sun11, Fengmin Shao12, Wenge Li13, Qiang He14, Hongli Jiang15, Hongli Lin16, Ping Fu17, Xinzhou Zhang18, Yinghong Liu19, Yonggui Wu20, ChunSheng Xi21, Meng Liang22, Zhijie Qu23, Jun Zhu24, Guangli Wu25, Yali Zheng26, Yu Na27, Ying Li28, Wei Li29, Guangyan Cai1, Xiangmei Chen1.   

Abstract

BACKGROUND/AIMS: Risk factor studies for acute kidney injury (AKI) in China are lacking, especially those regarding non-traditional risk factors, such as laboratory indicators.
METHODS: All adult patients admitted to 38 tertiary and 22 secondary hospitals in China in any one month between July and December 2014 were surveyed. AKI patients were screened according to the Kidney Disease: Improving Global Outcomes' definition of AKI. Logistic regression was used to analyze the risk factors for AKI, and Cox regression was used to analyze the risk of in-hospital mortality for AKI patients; additionally, a propensity score analysis was used to reconfirm the risk factors among laboratory indicators for mortality.
RESULTS: The morbidity of AKI was 0.97%. Independent risk factors for AKI were advancing age, male gender, hypertension, and chronic kidney disease. All-cause mortality was 16.5%. The predictors of mortality in AKI patients were advancing age, tumor, higher uric acid level and increases in Acute Physiologic Assessment and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores. The hazard ratio (HR) for mortality with uric acid levels > 9.1 mg/dl compared with ≤ 5.2 mg/dl was 1.78 (95% CI: 1.23 to 2.58) for the AKI patients as a group, and was 1.73 (95% CI: 1.24 to 2.42) for a propensity score-matched set.
CONCLUSION: In addition to traditional risk factors, uric acid level is an independent predictor of all-cause mortality after AKI.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Epidemiology; Mortality; Risk factors; Serum uric acid

Mesh:

Substances:

Year:  2017        PMID: 29136619     DOI: 10.1159/000484234

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Specificity of severe AKI aetiology and care in the elderly. The IRACIBLE prospective cohort study.

Authors:  Antoine Cardinale; Ziyad Messikh; Valery Antoine; Cédric Aglae; Pascal Reboul; Sylvain Cariou; Laurent Muller; Jean-Yves Lefrant; Olivier Moranne
Journal:  J Nephrol       Date:  2022-05-03       Impact factor: 4.393

2.  AKI!Now Initiative: Recommendations for Awareness, Recognition, and Management of AKI.

Authors:  Kathleen D Liu; Stuart L Goldstein; Anitha Vijayan; Chirag R Parikh; Kianoush Kashani; Mark D Okusa; Anupam Agarwal; Jorge Cerdá
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-21       Impact factor: 8.237

3.  Female sex reduces the risk of hospital-associated acute kidney injury: a meta-analysis.

Authors:  Joel Neugarten; Ladan Golestaneh
Journal:  BMC Nephrol       Date:  2018-11-08       Impact factor: 2.388

4.  Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries.

Authors:  Amayelle Rey; Valérie Gras-Champel; Gabriel Choukroun; Kamel Masmoudi; Sophie Liabeuf
Journal:  Fundam Clin Pharmacol       Date:  2022-01-25       Impact factor: 2.747

5.  Integrating electronic health data records to develop and validate a predictive model of hospital-acquired acute kidney injury in non-critically ill patients.

Authors:  Alfons Segarra; Jacqueline Del Carpio; Maria Paz Marco; Elias Jatem; Jorge Gonzalez; Pamela Chang; Natalia Ramos; Judith de la Torre; Joana Prat; Maria J Torres; Bruno Montoro; Mercedes Ibarz; Silvia Pico; Gloria Falcon; Marina Canales; Elisard Huertas; Iñaki Romero; Nacho Nieto
Journal:  Clin Kidney J       Date:  2021-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.